<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="Letter to the Editor" dtd-version="1.0"><front><journal-meta><journal-id journal-id-type="pmc">iarjcmb</journal-id><journal-id journal-id-type="pubmed">IARJCMB</journal-id><journal-id journal-id-type="publisher">IARJCMB</journal-id><issn>2789-6005</issn></journal-meta><article-meta><article-id pub-id-type="doi">https://doi.org/10.47310/iarjcmb.2023.v03i01.007</article-id><title-group><article-title>Anti-neurofascin-155 Antibodies in Guillain-Barre Syndrome</article-title></title-group><contrib-group><contrib contrib-type="author"><name><given-names>Josef</given-names><surname>Finsterer</surname></name></contrib><xref ref-type="aff" rid="aff-a" /></contrib-group><aff-id id="aff-a">Neurology and Neurophysiology Center, Vienna, Austria</aff-id><abstract>Anti-neurofascin-155 antibodies, Guillain-Barre syndrome, nodopathy, polyradiculopathy, nerve conduction</abstract></article-meta></front><body /><back /></article>